Key regions: Japan, India, Italy, Brazil, South Korea
Namibia, a country in southern Africa, has a developing healthcare system that is gradually improving access to healthcare services for its citizens. The Anti-Hypertensive Drugs market in Namibia is growing steadily as more people are diagnosed with hypertension and require medication to manage their condition.
Customer preferences: Namibians tend to prefer generic drugs over branded drugs due to their affordability. This preference has led to an increase in the availability of generic anti-hypertensive drugs in the market. Additionally, there is a growing demand for combination drugs that offer a more convenient way to manage hypertension.
Trends in the market: The Anti-Hypertensive Drugs market in Namibia is witnessing an increase in the availability of different classes of drugs, including diuretics, ACE inhibitors, calcium channel blockers, and beta-blockers. This increase is due to the growing number of people diagnosed with hypertension and the need for more treatment options. There is also a trend towards the use of fixed-dose combinations that offer a more convenient way to manage hypertension.
Local special circumstances: Namibia has a high prevalence of hypertension, which is attributed to lifestyle factors such as a diet high in salt, lack of physical activity, and obesity. The government has implemented measures to address these factors, including public health campaigns to promote healthy lifestyles and the introduction of policies to reduce the salt content in food products. Additionally, the government has made efforts to improve access to healthcare services in rural areas, where the prevalence of hypertension is high.
Underlying macroeconomic factors: Namibia has a small economy that is heavily dependent on mining and agriculture. The country has experienced economic challenges in recent years, including high unemployment and inflation rates. These challenges have impacted the affordability of healthcare services and medication for some Namibians. However, the government has made efforts to improve access to healthcare services through the introduction of a National Health Insurance scheme that aims to provide universal healthcare coverage.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
